To assess the actual clinical course with MKIs specifically in RET-positive MTC, we here retrospectively assessed the RET variant status in tissue samples from a prospective multi-center registry study at four German tertiary care centers and studied the outcomes specifically after treatment with MKIs in RET-positive cases. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.